PRODUCT INFORMATION

TPX-0022

Item No. 36118

CAS Registry No.:	2271119-26-5
Formal Name:	(7S)-3-amino-14-ethyl-11-fluoro-4,5,6,7,13,14-hexahydro-7-methyl-4-oxo-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile
Synonyms:	CSF1R-IN-2, CSF1R Inhibitor 2, Elzovantinib
MF:	$C_{20}H_{20}FN_7O_2$
FW:	409.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 215, 271 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TPX-0022 is supplied as a solid. A stock solution may be made by dissolving the TPX-0022 in the solvent of choice, which should be purged with an inert gas. TPX-0022 is soluble in the organic solvent ethanol at a concentration of approximately 5 mg/ml.

Description

TPX-0022 is an inhibitor of Src, MET, and CSF-1 receptor tyrosine kinase (FMS) kinases (IC_{50}s = 0.12, 0.14, and 0.76 nM, respectively).[1] It inhibits the proliferation of MKN45 and SNU-5 human gastric cancer cells (IC_{50}s = 0.2 and 0.17 nM, respectively), as well as Ba/F3 pro-B cells expressing TEL-CSF1R (IC_{50} = 19.3 nM). TPX-0022 (100 nM) inhibits cell migration of HCC827 human lung cancer cells. It inhibits tumor growth in an MKN45 mouse xenograft model when administered at doses of 10 and 30 mg/kg. TPX-0022 (10 mg/kg) also inhibits phosphorylation of MET at Tyr^{1234} and Tyr^{1349} in the same model.

Reference

1. Cui, J.J., Rogers, E.W., Ung, J., *et al.* Macrocyclic compounds and uses thereof. *TP Therapeutics, Inc.* **WO2019/023417A1** (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM